Basket cover image
15 handpicked stocks

Phoenixes

These remarkable companies have risen from the ashes of bankruptcy or severe financial distress. Our analysts have carefully selected businesses that emerged stronger, leaner, and ready for their second act of growth after successful restructuring.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at जून 17

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

AAL

American Airlines Group Inc.

AAL

Current price

$13.22

The airline holding company successfully emerged from Chapter 11 bankruptcy in 2013 after merging with US Airways.

GM

General Motors Co.

GM

Current price

$57.06

The iconic automaker underwent a landmark, government-supported bankruptcy reorganization in 2009 to become a leaner company.

PCG

PG&E Corporation

PCG

Current price

$15.60

California's largest utility emerged from Chapter 11 bankruptcy in 2020 after addressing massive liabilities from wildfires.

About This Group of Stocks

1

Our Expert Thinking

These companies represent the ultimate comeback stories in the business world. After facing bankruptcy or near-collapse, they've restructured operations, shed unprofitable segments, and strengthened their balance sheets. Now leaner and more focused, they offer significant growth potential as they enter their next chapter.

2

What You Need to Know

These stocks typically carry higher risk but also higher reward potential. They've completed formal bankruptcy proceedings or major financial restructuring, emerging with reduced debt and renewed business strategies. Their performance often accelerates during favorable economic cycles when their improved efficiency creates meaningful value.

3

Why These Stocks

Each company was selected because it has officially emerged from bankruptcy or financial distress with a viable path forward. Our experts look for new leadership teams, healthier balance sheets, and clear growth strategies that position these businesses to capitalize on their "second chance" at success.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+54.07%

Group Performance Snapshot

54.07%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 54.07% over the next year.

10 of 12

Stocks Rated Buy by Analysts

10 of 12 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🔄

The Comeback Effect

Companies that survive bankruptcy often outperform their peers in the years following restructuring. Their leaner operations and reduced debt create powerful potential for rapid growth that many investors overlook.

💰

Hidden Value Potential

These stocks are often undervalued as market sentiment takes time to shift from negative to positive. Getting in during this transition phase could mean capturing significant upside as the rebound story unfolds.

🌟

Second-Act Success Stories

From major airlines to energy giants, these companies have proven their resilience by surviving existential threats. Their battle-tested management teams and streamlined operations are positioned for success in ways their competitors aren't.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

Orphan Drug Moats: Leaders In Rare Disease

Orphan Drug Moats: Leaders In Rare Disease

The FDA's rejection of PTC Therapeutics' drug for a rare genetic disorder has delayed a new treatment option and created a significant setback for the company. This regulatory decision strengthens the competitive position of companies with already-approved therapies for rare diseases, highlighting the value of a proven drug portfolio.

View stocks
Nvidia's China Chip Pivot

Nvidia's China Chip Pivot

Nvidia is developing a new, compliant AI chip for China, aiming to recapture market share lost to U.S. export controls. This strategic pivot creates a ripple effect, potentially benefiting the entire semiconductor supply chain that supports the production and deployment of this advanced hardware.

View stocks
Navigating The Autonomous Driving Shakeout

Navigating The Autonomous Driving Shakeout

A class-action lawsuit against Tesla regarding its Full Self-Driving claims puts the company's marketing and technology under intense scrutiny. This legal challenge could boost demand for competing autonomous driving technologies, creating opportunities for companies that supply advanced sensors and software.

View stocks
View All

Frequently Asked Questions

Everything you need to know about the product and billing.